Overview
<cite index="5-2">Owkin, the agentic AI company, has announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, backed by a five-year license for K Pro, Owkin's AI (artificial intelligence) Scientist platform.</cite> The announcement was made via BusinessWire on June 5, 2026, and represents the latest expansion of an ongoing commercial relationship between the two organizations.
Deal Structure
<cite index="2-8,2-9,2-10">The five-year collaboration will use Owkin's K Pro AI scientist platform as the deployment foundation for agentic systems within Sanofi's research and development operations. Under the agreement, Owkin will lead the development of AI agents tailored specifically for Sanofi's drug development needs, delivered through K Pro under a five-year licensing structure.</cite>
<cite index="6-8,6-9">These intelligent systems are intended to function as autonomous research assistants capable of performing complex scientific and operational tasks across the drug development process, and will be deployed through K Pro to complement Sanofi's existing investments in agentic AI technologies.</cite>
Background: Prior Sanofi–Owkin Relationship
<cite index="4-3,4-4">The two companies have maintained a working relationship since 2021, underpinned by a €90 million ($103.6 million) collaboration centred on oncology target identification and patient subgrouping, with scope later broadened to include drug positioning within Sanofi's immunology pipeline.</cite> <cite index="5-5">This new collaboration represents the next evolution in that partnership.</cite>
About K Pro
<cite index="11-4,11-5">Owkin launched K Pro in October 2025 as a co-pilot bringing advanced agentic AI to biomedical research and drug development, designed to help pharmaceutical companies and biotechs make smarter decisions across the discovery and development pipeline and deliver decision-grade, data-driven biological insights.</cite>
<cite index="10-1,10-2">K Pro is an advanced drug portfolio decision-making platform that leverages agentic AI to connect biological understanding with clinically relevant outcomes. Built for accessibility, it empowers both technical and non-technical users to interrogate multimodal datasets—including genomic, imaging, clinical, and literature sources—using natural language, eliminating the need for coding or external tools.</cite>
<cite index="13-5">The platform integrates Owkin Zero, a biological large language model (LLM), and leverages comprehensive multimodal oncology datasets, including MOSAIC.</cite>
<cite index="11-8">Owkin's AI has previously delivered results for pharmaceutical clients, including preventing Phase 2 clinical trial futility by identifying high-risk combination therapy populations, and reducing trial duration by three years (35%) by identifying the right patient segment to inform enrolment.</cite>
Strategic Context
<cite index="1-8">In May 2026, Owkin had separately announced a multi-year license agreement with AstraZeneca to build biopharma agents for competitive intelligence and decision workflows.</cite> The Sanofi deal signals a broadening commercial push for the K Pro platform across major global pharmaceutical companies.
<cite index="2-5,2-6">The deal also comes amid growing industry and regulatory focus on the use of AI in drug development. The U.S. Food and Drug Administration's Center for Drug Evaluation and Research has reported rising use of AI in drug applications across nonclinical, clinical, and manufacturing stages, and issued draft guidance in 2025 outlining expectations for AI use in regulatory decision-making for drugs and biologics.</cite>
Sanofi's chief digital officer, Emmanuel Frenehard, emphasized the firm's commitment to AI-driven workflows. <cite index="1-3,1-4">"Across Sanofi, we are continually investing in frontier AI solutions with the potential to accelerate and improve decision-making throughout the drug development lifecycle," Frenehard said, adding that "by implementing purpose-built agentic systems into our workflows, we aim to empower our teams to operate with greater speed, depth, and confidence."</cite>
<cite index="4-7">The continued development of K Pro aligns with Owkin's broader goal of achieving biological artificial superintelligence, with the aim of transforming pharmaceutical research and development by addressing previously unsolved scientific challenges.</cite>